Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397610 | 1.00 | OPRL1 (0.47) | OPRL1OPRM1HTR1AHTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6396517 | 0.99 | OPRL1 (0.46) | OPRL1OPRM1HTR1AHTR7SIGMAR1 | |
| Citric Acid SCHEMBL7069932 | 0.92 | OPRL1 (0.42) | OPRL1OPRM1HTR1AHTR7SIGMAR1 | |
| Citric Acid SCHEMBL6396207 | 0.92 | OPRL1 (0.42) | OPRL1OPRM1HTR1AHTR7SIGMAR1 | |
| SCHEMBL6395194 | 0.86 | OPRL1 (0.54) | OPRL1OPRM1SIGMAR1SLC18A3 | |
| SCHEMBL6394179 | 0.86 | OPRL1 (0.54) | OPRL1OPRM1SIGMAR1SLC18A3 | |
| SCHEMBL6396088 | 0.85 | OPRL1 (0.50) | OPRL1OPRM1SIGMAR1SLC18A3 | |
| SCHEMBL6394941 | 0.85 | OPRL1 (0.50) | OPRL1OPRM1SIGMAR1SLC18A3 | |
| Hydrochloric Acid SCHEMBL7070297 | 0.85 | OPRL1 (0.53) | OPRL1OPRM1SIGMAR1SLC18A3 | |
| SCHEMBL6395355 | 0.85 | OPRL1 (0.50) | OPRL1OPRM1SIGMAR1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | ANDO KOJI (JP) | 2005-02-17 | — | — | US | claimed |
| US-20030078279-A1 | Spiropiperidine compounds as ligands for ORL-1receptor | PFIZER INC. | 2003-04-24 | — | — | US | claimed |
| US-20030078278-A1 | Spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. | 2003-04-24 | — | — | US | claimed |
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | ANDO KOJI (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1399432-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030078278-A1 | Spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030078279-A1 | Spiropiperidine compounds as ligands for ORL-1receptor | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003000677-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER PHARMACEUTICALS INC. (JP) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078278-A1 | Spiropiperidine compounds as ligands for ORL-1 receptor | OPRL1, OPRD1, OXER1 | OPRL1 1/4885OPRM1 10/4885HTR1A 444/4885 |
| US-20030078279-A1 | Spiropiperidine compounds as ligands for ORL-1receptor | OPRL1, OPRD1, OXER1 | OPRL1 1/4885OPRM1 11/4885HTR1A 412/4885 |
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | OPRL1, OXER1, OGFRL1 | OPRL1 1/4885OPRM1 14/4885HTR1A 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.